Montefiore

Phone
Menu

Dr. Gary S. Rogoff | Top Prosthodontist Bronx, NY

~ Chief of Prosthodontics and Director of the Prosthodontic Residency Program
Dr Gary S Rogoff | Prosthodontist Bronx NY

Dr. Gary S. Rogoff is Chief of Prosthodontics and Director of the Prosthodontic Residency Program at Montefiore. He is a native New Yorker, and received his Doctor of Dental Surgery degree (DDS) from New York University College of Dentistry in 1971. He received his Certificate of Advanced Training in Prosthodontics from the Eastman Dental Center in Rochester, NY, in 1974, and his Master of Science degree (MS) in Basic Medical Sciences from the University of Rochester Graduate School of Medicine and Dentistry in 1980. His first university academic appointment, in 1974, was to the faculty of The University of Rochester School of Medicine and Dentistry. In 1978 he moved to Boston and continued his teaching career with academic appointments at Tufts University School of Dental Medicine, the Forsyth Dental Institute, and the Harvard School of Dental Medicine. He has also maintained a private practice limited to prosthodontics, part-time, throughout this entire period. In July of 2007, Dr. Rogoff returned to New York City to join the Department of Dentistry at the Montefiore Medical Center.

Board Certifications

  • Diplomate, American Board of Prosthodontics

Professional Society Memberships

General Dental Organizations:

  • American Dental Association
  • Massachusetts Dental Society
  • Metropolitan District Dental Society, Boston, MA
  • American Academy of Dental Science

Honorary Dental Organizations:

  • Omicron Kappa Upsilon
  • American College of Dentists

Prosthodontic Dental Organizations:

  • Fellow, American College of Prosthodontists
  • American College of Prosthodontists, Massachusetts Section
  • American College of Prosthodontists, New York Section
  • Eastman Prosthodontic Alumni Association
  • Fellow, Academy of Prosthodontics
  • Fellow, Greater New York Academy of Prosthodontics
  • Academy of Osseointegration

Awards, Honors and Elected Offices

Dr. Rogoff has received numerous academic and professional awards. He is a recipient of the Bausch and Lomb Science Award from the University of Rochester, and a New York State Regents Fellowship in Dentistry at New York University. He was presented with the New York University Founders Day Award for Outstanding Scholarship and the New York University Club Award. He has also received the International College of Dentists Award for Outstanding Achievement, and the American Academy of Oral Medicine Award at New York University. Dr. Rogoff has been voted the Most Outstanding Presentation at the Postgraduate Course in Prosthodontics given by the U.S. Army Institute of Dental Research at the Walter Reed Army Medical Center, and he has been presented with a Scientific Investigation Award by the Greater New York Academy of Prosthodontics. Dr. Rogoff has served the Dental Profession as President of the New England Section of the American College of Prosthodontists, President of the Academy of Prosthodontics, President of the Academy of Prosthodontics Foundation, and President of the Greater New York Academy of Prosthodontics.

Presentations & Publications

Dr. Rogoff has presented more than 150 invited lectures and continuing education courses in Prosthodontics nationally and internationally, in over 40 states and 5 countries. His publications include original articles, review articles, videotapes, book chapters and a text book.

Bibliography

  1. Rogoff, G.S.; The Relationship of Endogenous Plasma Estrogens to the Maturation of Human Female Buccal Epithelium; Thesis, Master of Science, University of Rochester School of Medicine and Dentistry, Rochester, NY; 1980.
  2. Rogoff, G.S.; The Relationship of Endogenous Plasma Estrogens to the Maturation of Human Female Buccal Epithelium; Abstract, Momentum; Eastman Dental Center; 4:4:3, 1980.
  3. Rogoff, G.S.; The Estrogen Effect and the Human Buccal Mucosa; Abstract, Dental Outlook, Tufts University; 80:1:13, 1980.
  4. Rogoff, G.S.; Role of Dietary Calcium and Vitamin D in Alveolar Bone Health; Abstract, Federation of American Societies for Experimental Biology; Chicago, IL; April, 1983.
  5. Rogoff, G.S. and Galburt, R.B.; Calcium and Oral Health; Abstract, American Association for the Advancement of Science; New York, NY; May 1984.
  6. Rogoff, G.S., Galburt, R.B. and Nizel, A.E.; Role of Calcium and Vitamin D in Alveolar Bone Health; In: Calcium in Biological Systems; Plenum Publishing Co., New York, NY; 1985.
  7. Rogoff, G.S., and Shulman, L.B.; Implants and Implant Prosthetics: The Partially Edentulous Patient; Videotape, DENTSAT 1:3; CME-SAT Inc., Sarasota, FL; 1985.
  8. Shulman, L.B. and Rogoff, G.S.; Implants and Implant Prosthetics: The Completely Edentulous Patient; Videotape, DENTSAT 1:4; CME-SAT Inc., Sarasota, FL; 1985.
  9. Shulman, L.B., Rogoff, G.S., Savitt, E.D. and Kent, R.L.; Evaluation in Reconstructive Implantology; Dent. Clin. North Amer., 30:2:327; 1986.
  10. Shulman, L.B., and Rogoff, G.S.; Branemark Implant Reconstruction—Independent Fixed-Detachable Prostheses; Alpha Omegan, 80:3:45–51; 1987.
  11. Shulman, L.B. and Rogoff, G.S.; Dental Implantology; In: Peterson, L.J. et al, Contemporary Oral and Maxillofacial Surgery, C.V. Mosby Co., St. Louis; 1988.
  12. Halperin, A.R., Graser, G.N., Rogoff, G.S. and Plekavich, E. J.; Mastering the Art of Complete Dentures ; Textbook, Quintessence Publishing Co., Chicago, IL; 1989.
  13. Graser, G.N. and Rogoff, G.S.; Verification of Centric Relation; Compendium of Contin. Ed. Dent. 10: 2: 64-72, 1989.
  14. Rogoff, G.S. and Graser, G.N.; Overdentures for Acquired and Congenital Anomalies; Part I: Complete Dentures; Int. J. Pros., 3:3: 229-237, 1990.
  15. Graser, G. N. and Rogoff, G. S .; Overdentures for Acquired and Congenital Anomalies; Part II: Partial Overdentures ; Int. J . Pros., 3: 4: 361-367, 1990.
  16. Graser, G.N. and Rogoff, G.S.; Removable Partial Overdentures for the Special Patient; Dent. Clin. N. Amer.; 34:4: 741-758, 1990.
  17. Rogoff, G. S.; Facts About Implants ; Abstract in : Rogoff, G. S., Morgano, S., Vergo, T. and Lloyd, P.; The Dental Specialty of Prosthodontics: Services and Expertise in High Demand By the Elderly; Gerontological Society of America; The Gerontologist; 30: A: 292, 1930.
  18. Rogoff, G.S .; CeraOne Single-Tooth Replacement ; Illustrated interview in: Dental Implantology Update ; Ed. Perel , M. L.; 2: 5: 42 ; American Health Consultants, Atlanta, GA; 1991.
  19. Rogoff, G.S.; Osseointegrated Implant Prosthodontics; In: Current Opinion in Dentistry, Prosthodontics and Endodontics; Current Science; 2: 17-24, 1992.
  20. Wolfinger, G.J., Rogoff, G.S., Harrison, J.A. and Callum, J.O.; Prosthodontic Management of a Combination Transosteal/Endosteal Implant Reconstruction; J. Prosth. 5:2:76-83, 1996.

Contact Us Today

Call (888)-700-6623 to schedule a consultation with Dr. Gary S. Rogoff to learn how we can help you achieve your desired dental goals!

Medication Disclaimer

Essential Information on Medications: Saxenda®, Victoza®, Wegovy®, and Ozempic® are patented products of Novo Nordisk™, while Eli Lilly and Company™ produce Mounjaro™ and Zepbound. This website is not affiliated with, endorsed by, or connected to these companies or their products in any capacity. While these FDA-approved medications may be available through other sources, we do not provide them, and they are currently experiencing supply shortages. During such shortages, pharmacies might prepare compounded versions of these drugs, provided they comply with the Federal Food, Drug, and Cosmetic Act’s requirements. Compounded medications are valuable for patients with unique medical needs that FDA-approved drugs cannot address. However, it is important to note that compounded drugs are not FDA-approved, nor do they undergo premarketing evaluations for safety, effectiveness, or quality. The FDA has not assessed these medications for their intended uses, nor has the manufacturing process for compounded drugs been reviewed by the FDA.

Safety Information

Critical Details About Compounded Semaglutide

Compounded medications are legally allowed to be prescribed under federal law; however, they are not FDA-approved and do not undergo FDA evaluation for safety, efficacy, or production standards. At MontefioreDental, compounded semaglutide is prescribed based on an individualized medical assessment.

WARNING: Potential Risk of Thyroid C-Cell Tumors
Research in animals has linked semaglutide, the active ingredient in some GLP-1 receptor agonists, to thyroid tumors, including medullary thyroid carcinoma (MTC). It is unclear if semaglutide causes similar tumors in humans. Notify your healthcare provider immediately if you notice symptoms of thyroid cancer, such as neck lumps or swelling, hoarseness, swallowing difficulties, or shortness of breath. Compounded semaglutide is not suitable for individuals with personal or family histories of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Uses of Compounded Semaglutide
Compounded semaglutide is intended for use alongside a reduced-calorie diet and increased physical activity to manage chronic weight in adults who meet the following criteria:

  • A body mass index (BMI) of 30 kg/m² or higher (classified as obesity), or
  • A BMI of 27 kg/m² or higher (overweight) with at least one weight-related condition, such as type 2 diabetes, hypertension, or abnormal cholesterol levels.

Usage Restrictions

  • Do not use compounded semaglutide in combination with other GLP-1 receptor agonists or semaglutide-containing products.
  • Its safety and effectiveness when combined with other weight management medications have not been established.
  • Patients with a history of pancreatitis or gastroparesis have not been studied for this treatment.

Avoid Use If You:

  • Have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
  • Are diagnosed with type 1 diabetes, pancreatitis, or gastroparesis.
  • Are allergic to semaglutide or any inactive ingredients.
  • Have a history of suicidal thoughts or behavior.

Precautions and Warnings:

  • Acute Pancreatitis: Stop using the medication if pancreatitis is suspected.
  • Gallbladder Issues: Monitor for symptoms of gallbladder disease, including gallstones, and seek medical advice as needed.
  • Low Blood Sugar: When combined with insulin or similar medications, there is an increased risk of hypoglycemia. Regularly monitor blood sugar and adjust doses as recommended by your provider.
  • Kidney Health: Monitor kidney function, particularly in patients with renal impairment or those experiencing severe gastrointestinal effects.
  • Mental Health Concerns: Watch for mood changes, depression, or suicidal thoughts, and discontinue use if these symptoms occur.

Pregnancy and Fertility Considerations
Semaglutide may harm an unborn child. Avoid use during pregnancy or if planning to become pregnant. Stop treatment at least two months before attempting to conceive.

Common Side Effects:
Frequently reported side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, headaches, and low blood sugar in patients with type 2 diabetes.

Potential Drug Interactions:
Compounded semaglutide slows gastric emptying, which could impact the absorption of oral medications. Consult your healthcare provider to manage potential interactions effectively.